Efsubaglutide record · updated 7h ago

Metabolic & appetiteInflammation & immuneGrade C · preclinicalResearch use only

All 3 studies Jump to the evidence Compare

What is Efsubaglutide used for?

Research peptide discovered via AI researcher. peptide-based therapeutic

How it works: GLP-1 receptor agonist

Primarily researched for · Metabolic & appetite

Development stage

where Efsubaglutide sits between preclinical work and regulatory approval

1Cleared
Preclinical
Animal / in-vitro work
2Cleared
Phase 1
Safety in humans
3Current
Phase 2
Efficacy signal
4Not reached
Phase 3
Confirmatory trials
5Not reached
Approved
Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 13 registered trials. It describes the research record, not a recommendation.

Identity

NameEfsubaglutide

Chain length—

Molecular weight—

Formula—

Structure type—

ClassMetabolic

Research levelLimited Research

Discovered byThe Librarian · 2026

Pharmacology

MechanismGLP-1 receptor agonist

Route—

Half-life—

Time to peak—

Duration—

Extraction confidence0.70

Effect profile · 0–5

These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Aug 29, 2026. How this works →

Research stats

Total studies3

Human / animal / cellular0 / 2 / 1

Highest trial phasePhase 2

Years covered2026

Latest study1d ago

Publication history

20262026

Research funding

—no NIH grants found

Safety signals

FAERS reports3

Serious AEs in animal work—

Community reports—

Positive —Neutral —Negative —

Records

ChEMBL ClinicalTrials.gov DrugBank Google Scholar PubChem PubMed · 3 Semantic Scholar UniProt

Study register

3 rowsOpen in the library →

SortDate added ↓Publication year Evidence type Summary depth

Study	Type	Year	Summary depth
Colonic nutritional and physicochemical parameters drive gut microbiota dysbiosis in obesity: what we learned from the Ob-M-ARCOL model development. FindingNot reported in abstract.	In vitro	2026	Full text read0.70
Comprehensive safety evaluation of DW2009, a complex of <i>Lactiplantibacillus</i> C29 and fermented soybean powder. FindingNo observable adverse effect at 3000 mg/kg body weight/day over 90 days.	Animal	2026	Full text read0.70
Risk ranking and antimicrobial resistance of Shiga toxin-producing <i>Escherichia coli</i> of bovine origin. Finding6.7% STEC prevalence on hides, n=150.	Animal	2026	Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Efsubaglutide will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Efsubaglutide is discussed should be drawn from it.